IGM Biosciences received a mix of bullish, somewhat bullish, and indifferent analyst ratings in the last quarter. The average 12-month price target has decreased by 21.61% from the previous average, which may indicate uncertainty about the company's future performance. This could lead to a neutral short-term impact on the stock price.